Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Results clear on some things, not on others..I’m not a Dr.

<< Previous

Bullboard Posts

Next >>

Post by canadafanon May 25, 2023 5:31pm

243 Views

Post# 35464669

Results clear on some things, not on others..I’m not a Dr.

The results do show a clear improvement Pala + pactataxil alone.
cohort 2 vs #1.
beyond that. I'm not qualified to determine if this is over the top good or not.
No N.R., puzzles me.
Well tomorrow is yet another day....
The ambiguity does explain why a verbal communication & KOL followup is required.
Certainly not bad news.
The triplet combo, did not improve at all.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features